Pneumonia Caused By Pseudomonas aeruginosa Infection — Comprehensive Disease Report

Target disease: Pneumonia Caused By Pseudomonas aeruginosa Infection MONDO ID: MONDO:0037398 · Category: Infectious Disease Pathogen taxon: Pseudomonas aeruginosa — NCBI:txid287 (species); genus Pseudomonas NCBI:txid286 Investigation: 5 iterations · 9 confirmed findings · 61 papers reviewed · Report date 2026-09-30

Summary

Pneumonia caused by Pseudomonas aeruginosa is an opportunistic Gram-negative lower-respiratory-tract infection that predominantly afflicts hosts with compromised mechanical or immune barriers — mechanically ventilated ICU patients, neutropenic and immunocompromised patients, and people with structural lung disease such as cystic fibrosis (CF) and bronchiectasis. It is not a heritable Mendelian disorder; its "etiology" is infectious, with host genetics (most paradigmatically CFTR mutations) acting as susceptibility modifiers rather than causes. Clinically it is one of the leading causes of hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), and it is increasingly multidrug-resistant (MDR) and carbapenem-resistant (CRPA) — a WHO critical-priority pathogen.

The pathophysiology splits into two mechanistic branches. In acute pneumonia, the Type III Secretion System (T3SS) injects cytotoxic effectors (ExoU, ExoS, ExoT, ExoY) into host cells, while flagellin is sensed by TLR5 on airway epithelium and the T3SS is sensed by the NLRC4 inflammasome in alveolar macrophages, driving IL-1β-mediated neutrophilic inflammation, alveolar–capillary barrier destruction, acute lung injury/ARDS and, frequently, death. In chronic pneumonia (the CF/bronchiectasis paradigm), conversion to a mucoid, alginate-overproducing biofilm phenotype evades opsonic and non-opsonic phagocytosis and establishes lifelong airway persistence with progressive lung-function decline.

Prognosis is dominated by two modifiable factors — antimicrobial resistance and inappropriate initial empiric therapy — both of which sharply raise mortality. VAP attributable mortality is roughly 30%, and 28-day all-cause mortality in ventilated HAP/VAP trials remains ~20–26%. First-line management uses anti-pseudomonal β-lactams; ceftolozane/tazobactam was non-inferior to meropenem in the phase 3 ASPECT-NP trial. Prevention rests on ventilator-care bundles (with several traditional components now questioned), and emerging therapies include inhaled antibiotics, anti-virulence monoclonal antibodies, DNA vaccines, and bacteriophage therapy.

1. Disease Information

Overview. Pseudomonas aeruginosa pneumonia is a lung parenchymal infection caused by the ubiquitous, aerobic, non-fermenting Gram-negative bacillus P. aeruginosa. It occurs mainly as hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP), and as chronic airway infection in structural lung disease. Acute P. aeruginosa pneumonia predominantly affects immunocompromised, neutropenic, and mechanically ventilated patients (PMID: 25520826, PMID: 9570172).

Key identifiers. - MONDO: MONDO:0037398 - Causative organism — NCBI Taxonomy: Pseudomonas aeruginosa, txid287 - ICD-10: J15.1 (Pneumonia due to Pseudomonas); ICD-11: bacterial pneumonia with Pseudomonas as the causal agent - MeSH: "Pneumonia, Bacterial" + "Pseudomonas Infections" / "Pseudomonas aeruginosa" - OMIM/Orphanet: Not applicable as a Mendelian entity (infectious disease); CFTR/cystic fibrosis (OMIM 219700; Orphanet ORPHA:586) is the relevant host-susceptibility entry.

Synonyms / alternative names. Pseudomonas pneumonia; Pseudomonal pneumonia; P. aeruginosa lower respiratory tract infection; Pseudomonas aeruginosa HAP/VAP; nosocomial Pseudomonas pneumonia.

Data source type. This report aggregates disease-level resources (surveillance cohorts, randomized trials, mechanistic model-organism and in-vitro studies, and registry data) rather than individual EHR-derived patient records.

2. Etiology

Primary cause (infectious). The disease is caused by infection with P. aeruginosa. It is fundamentally an opportunistic infection: host predisposition defines who develops disease.

Risk factors (environmental / host). - Mechanical ventilation / endotracheal intubation — the dominant risk setting; VAP incidence is ~7–15% of ventilated patients (PMID: 30390751), and prolonged ventilation, reintubation and elevated CRP associate with VAP (PMID: 42592972). - Immunocompromise / neutropenia — P. aeruginosa was the most frequent organism in bacteremic pneumonia in neutropenic cancer patients (PMID: 9570172). - Structural lung disease — cystic fibrosis and bronchiectasis (chronic branch). - Prior antibiotic exposure — drives resistant strains and inappropriate initial therapy; associated with higher mortality (51.3% vs 34.0%, p<0.001) in Gram-negative severe sepsis (PMID: 21499086). - Comorbidities — diabetes (independently associated with MDR infection, adjusted OR 2.82), cardiovascular disease, COPD, hypertension (PMID: 42393552); ECMO support (PMID: 42685911); chest trauma with high injury-severity score and tracheostomy (PMID: 41978407).

Genetic (host susceptibility) risk factors. - CFTR mutations (cystic fibrosis). The paradigmatic host genetic risk factor for chronic pulmonary P. aeruginosa infection. CF produces progressive lung disease with chronic infection, mucus accumulation, airway inflammation and structural damage, with P. aeruginosa as a dominant chronic pathogen (PMID: 38702073, PMID: 41010996). The most common allele is F508del (PMID: 38742380). - Inflammasome variants. Gain-of-function variants in NLRP3/NLRC4 inflammasome genes have been associated with clinical outcomes in CF (PMID: 33848452).

Protective factors. No validated protective genetic variant is established for this infectious disease. Environmental/behavioral protection is essentially prevention of acquisition (see §13): avoiding intubation, minimizing sedation, early extubation and mobilization (PMID: 31585480). Innate effectors such as Cmpk2 enhance neutrophil phagocytosis and host survival (model-organism evidence; PMID: 40616692).

Gene–environment interactions. The clearest interaction is CFTR deficiency × environmental P. aeruginosa exposure → chronic mucoid airway infection. Prior-antibiotic environment × bacterial resistance genotype → inappropriate therapy → death is a second, treatment-relevant interaction.

3. Phenotypes

P. aeruginosa pneumonia presents as a bacterial pneumonia syndrome; phenotypes are acquired clinical manifestations, not congenital.

Quality-of-life impact. Acute P. aeruginosa pneumonia in ventilated patients prolongs mechanical ventilation (12.5 vs 7.3 days) and hospitalization (19.6 vs 12.2 days) (PMID: 42592972). In the chronic CF branch, persistent infection drives progressive lung-function decline, exacerbations, and reduced survival (PMID: 38702073).

4. Genetic / Molecular Information

No human causal gene produces P. aeruginosa pneumonia — it is infectious. Genetics operates on two axes:

(a) Host susceptibility / modifier genes (human). - CFTR (HGNC:1884; OMIM 602421) — loss-of-function mutations (F508del most common) cause CF and predispose to chronic P. aeruginosa airway infection (PMID: 38742380, PMID: 42774065). Variant classes include in-frame deletion (F508del), nonsense/stop-codon, splice, and gating variants; population-specific alleles (e.g., N1303K, G542X, 2789+5G>A enriched in Italy) exist (PMID: 42370441). - NLRP3 / NLRC4 — inflammasome gain-of-function variants associated with CF outcomes (PMID: 33848452). - TLR5, MUC1 — innate-sensing genes that modulate epithelial responses (PMID: 16239509, PMID: 22250084).

(b) Bacterial virulence & resistance loci (pathogen genome). - T3SS effector genes: exoU (phospholipase A2, most cytotoxic), exoS (ADP-ribosyltransferase + GAP), exoT (GAP), exoY (nucleotidyl cyclase); master regulator exsA (PMID: 25520826, PMID: 15972518). - Alginate biosynthesis: algD operon, regulator mucA (mucoid conversion) (PMID: 37009499). - Flagellin: fliC (TLR5 ligand) (PMID: 16239509). - Resistance determinants: carbapenemase and other AMR genes confirmed by whole-genome sequencing in high-risk clones (PMID: 41751514).

Epigenetics / chromosomal abnormalities: Not applicable to the disease as an infectious entity in humans.

5. Environmental Information

Infectious agent. Pseudomonas aeruginosa (NCBI txid287), an aerobic, motile, non-fermenting Gram-negative bacillus. It is environmentally ubiquitous (water, moist surfaces, hospital reservoirs, medical devices) and forms biofilms on ventilator circuits and endotracheal tubes.

Environmental / occupational factors. Hospital and ICU environments, contaminated respiratory equipment, and indwelling devices are the principal reservoirs; >90% of MDR carbapenem-resistant P. aeruginosa isolates in one large UAE survey originated in hospitals (PMID: 41826861).

Lifestyle factors. Not the primary drivers; smoking/COPD contribute to structural lung disease that raises susceptibility (PMID: 42393552).

6. Mechanism / Pathophysiology

Ordered causal chain

ACUTE CYTOTOXIC BRANCH (ventilated / immunocompromised host):

1. P. aeruginosa colonizes the lower airway (aided by ventilation, impaired clearance) → leads to contact with alveolar epithelium and macrophages.
2. Bacterial flagellin is recognized by TLR5 on the apical surface of airway epithelial cells → results in NF-κB activation and pro-inflammatory chemokine/cytokine transcription (PMID: 16239509). (MUC1 tethers to TLR5 and dampens this signal — a counter-regulatory branch; PMID: 22250084.)
3. The Type III Secretion System injects effectors ExoU/ExoS/ExoT/ExoY into host cells → causes direct cytotoxicity; ExoU (phospholipase A2) is most cytotoxic and induces mitochondrial damage in macrophages (PMID: 35130452).
4. Alveolar macrophages detect the T3SS → activate the NLRC4 inflammasome → caspase-1 → IL-1β/IL-1α release (PMID: 42779855). NLRC4 activation also attenuates macrophage phagocytosis, worsening bacterial persistence (inferred causal link from model organism; PMID: 33489931).
5. IL-1β-driven inflammation → massive neutrophil recruitment and alveolar–capillary barrier disruption → increased permeability, pulmonary edema, protein-rich BALF (demonstrated as ↑wet/dry ratio and ↑BALF protein in the T3SS-competent CHA strain vs exsA-null mutant) (PMID: 15972518).
6. → Acute lung injury / ARDS, hypoxemic respiratory failure, sepsis/septic shock → death in a substantial fraction.

CHRONIC PERSISTENCE BRANCH (CF / bronchiectasis host):

1. Impaired mucociliary clearance (e.g., CFTR loss) → chronic airway colonization.
2. mucA mutation → alginate overproduction → conversion to mucoid biofilm phenotype.
3. Alginate inhibits opsonic and non-opsonic phagocytosis by human (THP-1) and murine (MH-S) macrophages, blocking CD11b/CD14 receptor–ligand interactions (PMID: 37009499).
4. → immune evasion, chronic persistent infection, antibiotic tolerance → recurrent exacerbations, progressive lung-function decline, mortality (PMID: 38702073).

            P. aeruginosa in lower airway
                       |
     ┌─────────────────┴──────────────────┐
     ACUTE (T3SS+ / planktonic)          CHRONIC (mucoid / biofilm)
     |                                     |
   flagellin→TLR5→NF-κB (epi)          mucA → alginate overproduction
   T3SS→ExoU/S/T/Y (cytotoxic)         → blocks CD11b/CD14 phagocytosis
   T3SS→NLRC4 inflammasome→IL-1β        → immune evasion
     |                                     |
   neutrophil influx + barrier loss     chronic persistence, tolerance
     |                                     |
   ALI / ARDS / respiratory failure     progressive lung decline
     |                                     |
high acute mortality            recurrent exacerbations, ↓survival

Cell types & GO/CL terms. Alveolar epithelial cells (CL:0000066; type II CL:0002063), alveolar macrophages (CL:0000583), neutrophils (CL:0000775). Biological processes: T3SS-dependent cytotoxicity, inflammasome complex assembly (GO:0140738), NLRC4 inflammasome activation, IL-1β production (GO:0032611), TLR5 signaling (GO:0034146), neutrophil chemotaxis (GO:0030593), phagocytosis (GO:0006909). Subcellular: mitochondrion (GO:0005739) (ExoU damage), plasma membrane, extracellular alginate matrix.

Molecular profiling. Multi-omics of acute P. aeruginosa infection and mitochondrial gene-expression analysis of ARDS datasets (GEO) identified Cmpk2 as an innate-immune protective node enriched in neutrophils by scRNA-seq (PMID: 40616692, PMID: 40216004).

7. Anatomical Structures Affected

• Primary organ: Lung (UBERON:0002048), lung parenchyma / alveoli (alveolus UBERON:0002299), respiratory system (UBERON:0001004).
• Secondary involvement: Bloodstream (bacteremia/sepsis), systemic multi-organ dysfunction in septic shock; ARDS affects the alveolar–capillary unit bilaterally.
• Tissues: Airway and alveolar epithelium (apical surface where TLR5 is expressed on human tracheal epithelium; PMID: 16239509); pulmonary capillary endothelium; alveolar interstitium.
• Cells (CL): alveolar macrophages (CL:0000583), neutrophils (CL:0000775), alveolar type I/II epithelial cells (CL:0002062 / CL:0002063).
• Subcellular (GO CC): mitochondrion (GO:0005739), plasma membrane, cytosolic inflammasome.
• Localization / lateralization: Typically bilateral in VAP/ARDS; may be unilateral/multilobar in focal bronchopneumonia.

8. Temporal Development

• Onset (acute branch): Acute to subacute, developing over hours–days; VAP is defined as pneumonia arising >48 h after intubation, with early-onset (~58%) and late-onset (~42%) forms (PMID: 41939663).
• Onset (chronic branch): Insidious, beginning in childhood in CF and progressing over decades (PMID: 38702073).
• Progression: Acute disease can progress rapidly to ARDS, septic shock and death; the chronic branch follows a relapsing–remitting course of exacerbations superimposed on progressive decline.
• Duration: Acute pneumonia is treated over days–weeks; chronic P. aeruginosa airway infection is typically lifelong once mucoid biofilm is established.
• Remission: Acute disease can resolve with appropriate, timely antimicrobial therapy; chronic mucoid infection rarely eradicates. Critical intervention window: early appropriate empiric therapy (see §11) is the key modifiable determinant of outcome.

9. Inheritance and Population (Epidemiology)

Inheritance: Not applicable (infectious disease). Host susceptibility via CFTR is autosomal recessive.

Epidemiology (frequency as HAP/VAP pathogen).

Chronic CF branch: chronic P. aeruginosa infection affects ~30–37% of adults and ~5–7% of paediatric CF patients in the Italian CF Registry, declining with CFTR-modulator therapy (PMID: 38742380, PMID: 42370441).

Geographic distribution: Global; MDR/CRPA burden is rising, with regional variation and WHO critical-priority status (PMID: 42523687). Sex/age: Reflects the underlying ICU/comorbid population (older adults, male predominance in several cohorts).

10. Diagnostics

Clinical/lab tests. - Microbiology (gold standard): culture of respiratory specimens — endotracheal aspirate (ETA) or bronchoalveolar lavage (BAL), with semi-quantitative thresholds (≥10⁵ CFU/mL for ETA) (PMID: 41939663, PMID: 42801252). Antimicrobial susceptibility testing (CLSI) is essential given high MDR rates. - Inflammatory markers / biomarkers: CRP discriminates VAP (AUC 0.83; PMID: 42592972); leukocytosis; bronchoalveolar IL-1β correlates with bacterial burden and may mark ongoing/unresolved infection (PMID: 12626989). - Molecular/genomic: whole-genome sequencing profiles resistance and virulence (PMID: 41751514); metagenomic next-generation sequencing aids complex cases (PMID: 42661655). - Imaging: chest radiograph/CT showing infiltrates/consolidation (used with clinical criteria).

Clinical criteria. Modified Clinical Pulmonary Infection Score (CPIS >6), CDC/NHSN surveillance definitions for HAP/VAP; VAP requires pneumonia >48 h post-intubation (PMID: 41939663, PMID: 42393552).

Differential diagnosis. Other Gram-negative HAP/VAP pathogens (A. baumannii, K. pneumoniae), S. aureus pneumonia, aspiration pneumonitis, ARDS of non-infectious cause, pulmonary aspergillosis in the immunocompromised.

Genetic testing. Not for the infection itself; CFTR sequencing / sweat chloride testing is indicated when chronic P. aeruginosa infection suggests undiagnosed CF (diagnostic delay causes irreversible damage; PMID: 42774065).

11. Outcome / Prognosis

Mortality. - VAP attributable mortality ~30% (PMID: 18060758). - 28-day all-cause mortality in ventilated HAP/VAP (ASPECT-NP, Gram-negative pathogens): 20.1% (ceftolozane/tazobactam) vs 25.8% (meropenem) (PMID: 35022730); ~23.7–24.0% with severe respiratory failure (PMID: 36773112). - Overall HA-GNB in-hospital mortality up to ~40% in high-comorbidity cohorts (PMID: 42393552).

Dominant prognostic factors (modifiable). 1. Carbapenem/multidrug resistance — CR infections carry significantly higher mortality across pathogens including P. aeruginosa (multicentre Indian surveillance, 159,336 patients; PMID: 42707186). 2. Inappropriate initial therapy — prior-antibiotic exposure → inappropriate empiric therapy (45.4% vs 21.2%) → higher hospital mortality (51.3% vs 34.0%) (PMID: 21499086). 3. Shock/vasopressor use, severe organ failure (SOFA) (PMID: 36773112, PMID: 36457059).

Complications: bacteremia, septic shock, ARDS, multi-organ failure; prolonged ventilation and hospitalization; in CF, progressive respiratory failure and death (median age at death in Italian CF registry 43–57 years) (PMID: 38742380, PMID: 42370441).

12. Treatment

First-line pharmacotherapy — anti-pseudomonal β-lactams. - Ceftolozane/tazobactam (3 g q8h) — non-inferior to meropenem in the phase 3 double-blind ASPECT-NP trial (NCT02070757) for ventilated HABP/VABP; for Gram-negative pathogens 28-day ACM 20.1% vs 25.8%, clinical cure 60.6% vs 57.1%, microbiologic eradication 73.0% vs 67.9%; P. aeruginosa comprised 25.0% of baseline LRT pathogens (PMID: 35022730). Efficacy held across renal-clearance and organ-failure subgroups (PMID: 34600585, PMID: 36773112). (NCIT: Ceftolozane-Tazobactam.) - Meropenem/carbapenems — comparator standard (PMID: 35022730). (NCIT: Meropenem.) - Other anti-pseudomonal agents: piperacillin-tazobactam, cefepime, ceftazidime, ceftazidime-avibactam, aztreonam, fluoroquinolones, aminoglycosides (guided by susceptibility, given high resistance rates).

For carbapenem-resistant P. aeruginosa (CRPA). Indian ICU guidelines (GRADE) favor non-polymyxin regimens for CRPA where efficacy is comparable but polymyxin toxicity is higher (42.1% vs 17.9%) (PMID: 42523687). Colistin remains active against many MDR isolates (80% colistin-S in an Egyptian VAP series) (PMID: 41877050).

Adjunctive / inhaled therapy. High-dose inhaled colistin followed by inhaled amikacin/tobramycin plus systemic therapy achieved clinical improvement and microbiologic eradication in MDR P. aeruginosa HAP/VAP despite in-vitro resistance, via high intrapulmonary concentrations (PMID: 42807670, PMID: 18060758).

Experimental / advanced therapeutics. - Anti-virulence monoclonal antibodies: fully human antibody cocktail targeting PcrV (T3SS tip), exotoxin A, and PA0833 gave broad-spectrum protection (PMID: 42662857); complement-activating CoMiX targeting Psl improved survival in murine pneumonia (PMID: 40961506). - Bacteriophage therapy: inhaled phage case series showed clinical/microbiological improvement without major adverse events (PMID: 41887374); murine efficacy depends on synergy with neutrophils, and alveolar macrophages can limit phage density (PMID: 40595615).

Supportive care: mechanical ventilation, oxygenation, hemodynamic support for sepsis, source control (device management), antimicrobial stewardship.

13. Prevention

Primary prevention (avoid acquisition). Ventilator-care bundles are central. The 2026 SIAARTI consensus endorsed subglottic secretion drainage and endotracheal cuff-pressure control; it did not recommend routine chlorhexidine oral care (outside cardiac surgery) and questioned selective digestive decontamination (SDD) (PMID: 42415225). Objectively beneficial measures include avoiding intubation, minimizing sedation, spontaneous awakening/breathing trials, early extubation and mobilization; oral chlorhexidine may increase mortality and stress-ulcer prophylaxis may facilitate pneumonia; SDD lowers VAP/mortality in low-resistance but not high-resistance ICUs (PMID: 31585480, PMID: 28759469, PMID: 32486132).

Secondary prevention. Early recognition/risk stratification (ISS, tracheostomy timing, CRP, ventilation duration) (PMID: 41978407); antimicrobial stewardship to preserve appropriate empiric therapy (PMID: 42393552).

Tertiary prevention. Infection control to prevent MDR spread (>90% of MDR-CRPA hospital-sourced; PMID: 41826861); CFTR-modulator therapy reduces chronic P. aeruginosa prevalence in CF (PMID: 42370441).

Immunization (experimental). No licensed vaccine. An OprF/PcrV bivalent DNA vaccine with hydrogel delivery reduced bacterial burden and improved survival in a murine pneumonia model (PMID: 38359491).

14. Other Species / Natural Disease

• Taxonomy of pathogen: Pseudomonas aeruginosa (NCBI txid287); broad host range.
• Cross-species susceptibility: P. aeruginosa pneumonia and infection occur across mammals; it is an opportunistic veterinary pathogen. Experimental infection is established in mice, rats, and zebrafish (PMID: 15972518, PMID: 40616692).
• Comparative mechanisms: Innate sensing (TLR5, NLRC4 inflammasome) and T3SS-mediated cytotoxicity are conserved across mammalian hosts, enabling model-organism study.
• Zoonotic potential: Environmental/opportunistic rather than classically zoonotic.

15. Model Organisms

Recapitulation & limitations: Mouse/rat models faithfully reproduce acute T3SS-driven neutrophilic lung injury and inflammasome biology and are the workhorse for therapeutic testing; they less faithfully capture chronic human mucoid biofilm persistence, the full MDR resistance landscape, and human comorbidity context. Phage-therapy models further reveal immune–phage feedback (macrophages reduce phage density) that complicates translation (PMID: 40595615).

Key Findings (with statistical evidence)

F001 — T3SS is the principal acute virulence determinant. In a rat ALI model, the T3SS-expressing CHA strain caused significantly greater lung injury (higher wet/dry ratio and BALF protein at 12 h), increased A549 cytotoxicity, decreased clearance and increased mortality vs the isogenic exsA-null mutant CHA-D1. Four effectors — ExoS, ExoT, ExoU, ExoY — are canonical (PMID: 15972518, PMID: 25520826). The T3SS "is involved in lung injury, septic shock, and a poor patient outcome."

F002 — Leading MDR HAP/VAP pathogen. 3rd-ranked HAP pathogen in a 37-hospital Chinese cohort (13.73%); 39.2% of ICU VAP with 85.1% MDR in an Egyptian series; 2nd-ranked (34.0%) in a Saudi HA-GNB cohort (PMID: 41758741, PMID: 41877050, PMID: 42393552).

F003 — Ceftolozane/tazobactam non-inferior; mortality ~20–26%. ASPECT-NP: Gram-negative 28-day ACM 20.1% vs 25.8% (C/T vs meropenem); P. aeruginosa 25.0% of pathogens (PMID: 35022730).

F004 — Mucoid alginate/biofilm mediates immune evasion. In mucoid FRD1 vs algD mutant, alginate inhibited opsonic and non-opsonic phagocytosis by human and murine macrophages (PMID: 37009499).

F005 — Prevention rests on modifiable bundles; some components questioned. SIAARTI 2026 endorsed subglottic drainage and cuff-pressure control, not routine chlorhexidine; VAP incidence ~7–15% (PMID: 42415225, PMID: 30390751).

F006 — Host predisposition defines risk; CFTR/CF is the chronic paradigm. (PMID: 38702073, PMID: 9570172, PMID: 35927044).

F007 — Resistance and inappropriate initial therapy dominate prognosis. CR infections carry higher mortality across pathogens (PMID: 42707186); inappropriate initial therapy → 51.3% vs 34.0% mortality (PMID: 21499086); attributable VAP mortality ~30% (PMID: 18060758).

F008 — Emerging adjunctive/experimental therapies. Inhaled antibiotics, anti-virulence mAbs (PcrV/ETA/PA0833), DNA vaccine (OprF/PcrV), and bacteriophage therapy (PMID: 42807670, PMID: 42662857, PMID: 38359491, PMID: 41887374).

F009 — Innate sensing via TLR5 and NLRC4 drives IL-1β neutrophilic injury. TLR5 recognizes flagellin (PMID: 16239509); alveolar macrophages detect T3SS → NLRC4 → IL-1β (PMID: 42779855); ExoU damages mitochondria (PMID: 35130452); NLRC4 activation attenuates phagocytosis and drives pulmonary damage (PMID: 33489931).

Mechanistic Model / Interpretation

The nine findings cohere into a two-branch model in which the same pathogen produces two clinically distinct diseases depending on host context and bacterial phenotype. The acute branch is a cytotoxic + hyperinflammatory process: T3SS injection (F001, F009) both directly kills epithelial/immune cells (ExoU phospholipase, mitochondrial damage) and triggers NLRC4-inflammasome IL-1β release, while flagellin–TLR5 amplifies NF-κB signaling. The convergent output is neutrophil-driven destruction of the alveolar–capillary barrier → ARDS → death. This branch dominates the ICU/ventilated/neutropenic population (F002, F006).

The chronic branch is an immune-evasion + persistence process: mucoid conversion (mucA→alginate) shields the biofilm from phagocytosis (F004), producing lifelong infection in structurally abnormal airways (CF/bronchiectasis; F006). Here the host genome (CFTR) is the key permissive factor.

Superimposed on both branches is the resistance/therapy axis (F002, F003, F007): outcomes are governed less by intrinsic virulence than by whether the organism is MDR/CRPA and whether initial empiric therapy is appropriate. This reframes prognosis as substantially modifiable through stewardship, rapid diagnostics, and next-generation agents (F003, F008). Prevention (F005) closes the loop by reducing acquisition upstream of all mechanisms.

Evidence Base

Limitations and Knowledge Gaps

• No dedicated dataset was analyzed; this is a literature-synthesis report, so all statistics derive from published cohorts/trials, each with their own design limitations (single-center retrospective series, subgroup analyses, non-inferiority framing).
• Attribution vs association: P. aeruginosa-attributable mortality is hard to isolate from severe underlying illness; the ~30% VAP figure is not pathogen-specific.
• Mechanistic data are largely model-organism/in-vitro (rat, mouse, zebrafish, cell lines). Human causal validation of the TLR5→NLRC4→IL-1β chain is inferential.
• Host genetics beyond CFTR and inflammasome variants are poorly defined; no robust human GWAS for P. aeruginosa pneumonia susceptibility was identified.
• Emerging therapies (mAbs, phage, DNA vaccine) rest on preclinical/case-series evidence without phase 3 RCT confirmation.
• Ontology mappings (ICD, HPO, GO, CL, UBERON, NCIT) are expert-suggested here and should be curator-verified.

Proposed Follow-up Experiments / Actions

1. Stratify prognosis by T3SS genotype (exoU vs exoS). Prospectively test whether exoU⁺ clinical isolates predict worse ARDS/mortality, linking F001 to human outcomes.
2. Clinical validation of PcrV-targeted anti-virulence mAbs in ventilated HABP/VABP RCTs, building on preclinical protection (PMID: 42662857).
3. Controlled trials of inhaled adjunctive antibiotics for MDR/CRPA VAP with pharmacokinetic/pharmacodynamic endpoints (PMID: 42807670).
4. Phage–immune interaction studies to define dosing that overcomes macrophage-mediated phage clearance (PMID: 40595615).
5. Biomarker-guided stewardship using CRP/IL-1β and rapid resistance genotyping to shorten time to appropriate therapy (addresses F007).
6. Host-directed therapy targeting the NLRC4 inflammasome / Cmpk2–STING axis to rebalance protective vs damaging inflammation (PMID: 33489931, PMID: 40616692).
7. Advance OprF/PcrV vaccine toward first-in-human trials in high-risk ICU/CF populations (PMID: 38359491).

Report compiled from 5 investigation iterations, 9 confirmed findings, and 61 reviewed papers. Evidence types span human clinical (surveillance cohorts, ASPECT-NP RCT), model organism (rat/mouse/zebrafish), in-vitro (A549/THP-1/MH-S/HEK293), and computational (multi-omics/GEO) sources.

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.3.0rc3.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• HP:0001945 (1 mention) - the report calls it "Common"; HP calls it Fever
• HP:0012735 (1 mention) - the report calls it "Common"; HP calls it Cough
• HP:0002094 (1 mention) - the report calls it "Common"; HP calls it Dyspnea
• HP:0025440 (1 mention) - the report calls it "Common (VAP)"; HP calls it Warm reactive autoantibody positivity
• HP:0001974 (1 mention) - the report calls it "Common"; HP calls it Increased total leukocyte count
• HP:0011227 (1 mention) - the report calls it "Common (PMID: 42592972)"; HP calls it Elevated circulating C-reactive protein concentration
• HP:0031977 (1 mention) - the report calls it "Diagnostic"; HP calls it Increased vertical cup-to-disc ratio - 0.9
• HP:0033677 (1 mention) - the report calls it "T3SS-driven subset"; HP calls it Acute respiratory distress syndrome
• UBERON:0002048 (1 mention) - the report calls it "Primary organ: Lung"; UBERON calls it lung**

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.